Skip to content

A Randomized Controlled Trial Study Protocol of Modified Mahuang-Fuzi-Xixin Decoction in the Treatment of Patients with Mild Bronchial Asthma During Acute Exacerbation

A Randomized Controlled Trial Study Protocol of Modified Mahuang-Fuzi-Xixin Decoction in the Treatment of Patients with Mild Bronchial Asthma During Acute Exacerbation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003457
Enrollment
Unknown
Registered
2020-07-05
Start date
2020-07-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Interventions

Sponsors

Affiliated Hospital of Chengdu University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 45 years old, both male and female; 2. According to the "guidelines for prevention and treatment of bronchial asthma" formulated by the asthma group of Respiratory Society of Chinese Medical Association in 2016, bronchial asthma was diagnosed as mild in acute attack stage; 3. Patients who meet the diagnostic criteria of TCM asthma syndrome "lung kidney yang deficiency syndrome"; 4. Patients with good ability to read, understand and write research related materials, and voluntarily comply with all trial requirements; 5. Patients who voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with respiratory tract infection within 4 weeks; 2. Patients with chronic obstructive pulmonary disease, interstitial lung disease, active pulmonary tuberculosis, bronchiectasis and other chronic lung diseases that need intervention or treatment; 3. Patients with severe mental and psychological disorders, cardiovascular, liver and kidney, endocrine, hematopoietic system, malignant tumor and other serious primary diseases; 4. Patients who take antibiotics within 3 months and take yogurt or probiotics within 1 month; 5. Patients who are unwilling or unable to change the current treatment plan; 6. Patients who are known to be allergic to the test drug or some traditional Chinese medicine in the test drug; 7. Women in lactation, pregnancy or preparing for pregnancy; 8. Patients who have participated in other clinical studies in recent six months.

Design outcomes

Primary

MeasureTime frame
Peak expiratory flow rate;

Secondary

MeasureTime frame
asthma control test score;Dose of Salbutamol sulfate aerosol;curative effect of Traditional Chinese Medicine Syndrome;Forced expiratory volume in one second;Immunoglobulin E;Asthma Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactLiao Tingting

Affiliated Hospital of Chengdu University of traditional Chinese Medicine

liaotingting00@163.com+86 18982196620

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026